VIA
NKTR icon

Virtus Investment Advisers’s Nektar Therapeutics NKTR Stock Holding History

Virtus Investment Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Buy
5,510
+526
+11% +$38.5K 0.09% 302
2026
Q1 		$359K Buy
4,984
+121
+2% +$6.89K 0.1% 257
2025
Q4 		$206K Buy
+4,863
New +$272K 0.06% 367

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's NKTR Position: Q2 2026 in Review

Virtus Investment Advisers increased its Nektar Therapeutics (NKTR) stake by 11% in Q2 2026, buying an estimated $38.5K and bringing the position to 5,510 shares worth $385K. The position accounts for 0.09% of the portfolio, ranked #302.

Virtus Investment Advisers first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Virtus Investment Advisers held 5,510 shares of Nektar Therapeutics worth $385K as of Q2 2026.
  • Virtus Investment Advisers bought 526 Nektar Therapeutics shares in Q2 2026, an estimated $38.5K.
  • Nektar Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #302 holding.
  • Virtus Investment Advisers first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.